Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 plus trastuzumab with or without chemotherapy in advanced unresectable/metastatic HER2-positive colorectal cancer
CTR20263682Phase 2Active
- Sponsor
- HyBioPharma
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of hlx22, trastuzumab in colorectal cancer (CRC), sponsored by HyBioPharma. Started Sep 2026; status: active.
02
Drugs
hlx22trastuzumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on CTR20263682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263682.